Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer

Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

(2012) Vassiliki A. Papadimitrakopoulou et al.   Journal of Thoracic Oncology

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

(2012) Vassiliki Papadimitrakopoulou   Journal of Thoracic Oncology

Natural history, management and pharmacokinetics of Everolimus-induced-oral ulcers: Insights into compliance issues

(2011) Charles Ferté et al.   EUROPEAN JOURNAL OF CANCER

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

(2011) Phuong K. Morrow et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1

(2011) Kathy Gately et al.   JOURNAL OF CLINICAL PATHOLOGY

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

(2011) Sylvie Négrier et al.   LANCET ONCOLOGY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

(2010) Katharine A. Price et al.   Journal of Thoracic Oncology

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy

(2010) Xia Pu et al.   LUNG CANCER

Targeting Epidermal Growth Factor Receptor-Associated Signaling Pathways in Non-Small Cell Lung Cancer Cells: Implication in Radiation Response

(2010) E. J. Choi et al.   MOLECULAR CANCER RESEARCH

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

(2009) J.-C. Soria et al.   ANNALS OF ONCOLOGY

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

(2009) Silvia La Monica et al.   BIOCHEMICAL PHARMACOLOGY

Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations

(2009) G. Konstantinidou et al.   CANCER RESEARCH

Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non-Small Cell Lung Cancer

(2009) A. Yoshizawa et al.   CLINICAL CANCER RESEARCH

From Theoretical Synergy to Clinical Supra-Additive Toxicity

(2009) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY